Different Endpoints Drive HAE Drugs On Road To Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With four drugs in the space, hereditary angioedema is an unusually well-served orphan disease. But the rare condition still has no clear path for efficacy assessment.